Neurymenolide A, a Novel Mitotic Spindle Poison from the New Caledonian Rhodophyta
Apoptosis
/ drug effects
Bone Neoplasms
/ drug therapy
Cell Line, Tumor
Drug Screening Assays, Antitumor
Hep G2 Cells
Humans
K562 Cells
MCF-7 Cells
Macrolides
/ chemistry
Microtubules
/ pathology
Mitosis
/ drug effects
Necrosis
/ drug therapy
Osteosarcoma
/ drug therapy
Pyrones
/ chemistry
Rhodophyta
/ chemistry
Spindle Apparatus
/ drug effects
New Caledonia
Phacelocarpus neurymenioides
Rhodophyta
apoptosis
mitotic catastrophe
mitotic spindle poison
necrosis
neurymenolide A
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
01 Feb 2019
01 Feb 2019
Historique:
received:
17
12
2018
revised:
21
01
2019
accepted:
23
01
2019
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
27
4
2019
Statut:
epublish
Résumé
The marine α-pyrone macrolide neurymenolide A was previously isolated from the Fijian red macroalga,
Identifiants
pubmed: 30717235
pii: md17020093
doi: 10.3390/md17020093
pmc: PMC6410418
pii:
doi:
Substances chimiques
Macrolides
0
Pyrones
0
neurymenolide A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Government of New Caledonia
ID : Thesis Grant
Organisme : Institut National Du Cancer
ID : NECROTRAIL
Organisme : Institut National Du Cancer
ID : Marine Natural Products
Organisme : Ligue Contre le Cancer
ID : CSIRGO
Organisme : European Union's Horizon 2020 research and innovation programme
ID : 654008
Organisme : ANR/Investissements d'Avenir program via the OCEANOMICs project
ID : ANR-11-BTBR-0008
Organisme : Cancéropôle PACA
ID : Marine Natural Products
Organisme : Région Bretagne
ID : ARED Fellowship program
Références
J Cell Biol. 2000 Jan 24;148(2):259-70
pubmed: 10648559
Nature. 2000 Sep 7;407(6800):41-7
pubmed: 10993066
J Nat Prod. 2001 Jul;64(7):907-10
pubmed: 11473421
Trends Pharmacol Sci. 2003 Jul;24(7):361-5
pubmed: 12871669
Nat Rev Cancer. 2004 Apr;4(4):253-65
pubmed: 15057285
Org Lett. 2009 Jan 1;11(1):225-8
pubmed: 19053716
Curr Opin Cell Biol. 2009 Feb;21(1):51-8
pubmed: 19185479
J Cell Sci. 2009 Apr 15;122(Pt 8):1134-44
pubmed: 19299467
J Cell Sci. 2009 Aug 1;122(Pt 15):2579-85
pubmed: 19625502
Anticancer Res. 2009 Aug;29(8):2993-6
pubmed: 19661306
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Crit Rev Oncol Hematol. 2012 Feb;81(2):163-84
pubmed: 21493087
Physiol Rev. 2011 Jul;91(3):973-1007
pubmed: 21742793
Cell Death Differ. 2012 Jan;19(1):107-20
pubmed: 21760595
Annu Rev Biochem. 2012;81:561-85
pubmed: 22482908
Angew Chem Int Ed Engl. 2012 Jul 9;51(28):6929-33
pubmed: 22674881
Curr Opin Cell Biol. 2013 Feb;25(1):14-22
pubmed: 23092753
J Chem Ecol. 2012 Oct;38(10):1203-14
pubmed: 23108534
J Nat Med. 2014 Jan;68(1):1-10
pubmed: 23564068
Curr Opin Pharmacol. 2013 Aug;13(4):519-28
pubmed: 23583638
Biochem Pharmacol. 2013 Sep 15;86(6):703-10
pubmed: 23886991
Nat Prod Rep. 2013 Sep;30(9):1158-64
pubmed: 23896896
Acc Chem Res. 2014 Mar 18;47(3):925-38
pubmed: 24279341
Mol Oncol. 2014 Dec;8(8):1404-18
pubmed: 24950801
Angew Chem Int Ed Engl. 2015 Sep 28;54(40):11754-9
pubmed: 26276764
Mediators Inflamm. 2015;2015:146282
pubmed: 26491220
Mar Drugs. 2016 Mar 16;14(3):null
pubmed: 26999165
Clin Cancer Res. 2017 Jul 15;23(14):3489-3498
pubmed: 28364015
Bioorg Med Chem Lett. 2018 Jan 15;28(2):53-60
pubmed: 29223590